Search research articles
Contact Us
Filters
Showing results (61-70 of 111) with videos related to
Page
of 12
Sort By:
Vaccine
|
May 29, 2007
Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults
Nilima Kshirsagar, Naidu Mur, Urmila Thatte, et al.
Journal of Medical Virology
|
June 11, 2024
Evaluation of monkeypox- and vaccinia-virus neutralizing antibodies before and after smallpox vaccination: A sero-epidemiological study
Serena Marchi, Giulia Piccini, Paolo Cantaloni, et al.
Haematologica
|
May 7, 2013
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials
Pier Luigi Zinzani, Simonetta Viviani, Antonella Anastasia, et al.
Journal of Immunology Research
|
September 12, 2022
Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination
Francesca Dapporto, Serena Marchi, Margherita Leonardi, et al.
Lancet (London, England)
|
September 15, 2012
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
Arunee Sabchareon, Derek Wallace, Chukiat Sirivichayakul, et al.
The Lancet. Infectious Diseases
|
October 26, 2017
A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial
Sirintip Sricharoenchai, Chukiat Sirivichayakul, Kulkanya Chokephaibulkit, et al.
European Journal of Haematology
|
August 2, 2006
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis
Carlo Visco, Gianpaolo Nadali, Theodoros P Vassilakopoulos, et al.
Blood
|
September 30, 2018
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
Craig H Moskowitz, Jan Walewski, Auayporn Nademanee, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 11, 2015
Safety Monitoring in Group A Meningococcal Conjugate Vaccine Trials: Description, Challenges, and Lessons
Godwin C Enwere, Gandhali Paranjape, Prasad S Kulkarni, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 11, 2015
Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010-2013
Fabien V K Diomandé, Téné M Yaméogo, Kirsten S Vannice, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 111) with videos related to
Sort By:
Page
of 12
Vaccine
|
May 29, 2007
Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults
Nilima Kshirsagar, Naidu Mur, Urmila Thatte, et al.
Journal of Medical Virology
|
June 11, 2024
Evaluation of monkeypox- and vaccinia-virus neutralizing antibodies before and after smallpox vaccination: A sero-epidemiological study
Serena Marchi, Giulia Piccini, Paolo Cantaloni, et al.
Haematologica
|
May 7, 2013
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials
Pier Luigi Zinzani, Simonetta Viviani, Antonella Anastasia, et al.
Journal of Immunology Research
|
September 12, 2022
Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination
Francesca Dapporto, Serena Marchi, Margherita Leonardi, et al.
Lancet (London, England)
|
September 15, 2012
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
Arunee Sabchareon, Derek Wallace, Chukiat Sirivichayakul, et al.
The Lancet. Infectious Diseases
|
October 26, 2017
A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial
Sirintip Sricharoenchai, Chukiat Sirivichayakul, Kulkanya Chokephaibulkit, et al.
European Journal of Haematology
|
August 2, 2006
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis
Carlo Visco, Gianpaolo Nadali, Theodoros P Vassilakopoulos, et al.
Blood
|
September 30, 2018
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
Craig H Moskowitz, Jan Walewski, Auayporn Nademanee, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 11, 2015
Safety Monitoring in Group A Meningococcal Conjugate Vaccine Trials: Description, Challenges, and Lessons
Godwin C Enwere, Gandhali Paranjape, Prasad S Kulkarni, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 11, 2015
Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010-2013
Fabien V K Diomandé, Téné M Yaméogo, Kirsten S Vannice, et al.
Page
of 12